The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers

Morris, John C.; Weıntraub, Sandra; Chui, Helena C.; Cummings, Jeffrey L.; DeCarli, Charles; Ferris, Steven; Foster, Norman L.; Galasko, Douglas; Graff‐Radford, Neill R.; Peskind, Elaine R.; Beekly, Duane; Ramos, Erin M.; Kukull, Walter A.

doi:10.1097/01.wad.0000213865.09806.92

Cited by 793 publications

(860 citation statements)

References 15 publications

Supporting

Mentioning

853

Contrasting

Unclassified

Order By: Relevance

“…We are pleased to see that, through the National Alzheimer Coordinating Center (NACC), AD centers are now strongly encouraged to use the set of carefully evaluated, predetermined measures selected for the Uniform Data Set. 65 The CERAD materials remain in demand. The de-identified database has been archived with NACC.…”

Section: Cerad's Legacymentioning

confidence: 99%

Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty years

Fillenbaum

Belle

Morris

et al. 2008

Alzheimer's & Dementia

Self Cite

372

274

View full text Add to dashboard Cite

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) was funded by the National Institute on Aging in 1986 to develop standardized, validated measures for the assessment of Alzheimer's disease (AD). The present report describes the measures that CERAD developed during its first decade, and their continued use in their original and translated forms. These measures include clinical, neuropsychological, neuropathological and behavioral assessments of AD, and also assessment of family history and parkinsonism in AD. An approach to evaluating neuroimages did not meet the standards desired. Further evaluations which could not be completed because of lack of funding (but where some materials are available), include evaluation of very severe AD, and of service use and need by patient and caregiver. The information that was developed in the U.S. and abroad permits standardized assessment of AD in clinical practice, facilitates epidemiological studies, and provides information valuable for individual and public health planning. CERAD materials and data remain available for those wishing to use them. KeywordsConsortium to Establish a Registry for Alzheimer's Disease; CERAD; Alzheimer's disease; clinical assessment; neuropsychological assessment; neuropathological assessment; norms; prevalence; incidence BackgroundDementing disorders have long been recognized, 1 with the identification of Alzheimer's disease (AD) typically dated back to Alzheimer's century-old paper. 2 Although considerable attention has been paid to Alzheimer's disease and substantial progress has been made in identifying its characteristics, nevertheless much remains unclear. As diagnostic procedures improve, the complexities of this disease become more apparent, and the threat it imposes becomes increasingly evident. In the population 65 years of age and older, both the incidence and prevalence of this disorder double every succeeding five years, 3 with estimated prevalence as high as 40% among those over the age of 85. AD, not recognized as a leading cause of death in 1980, was recognized as the fifth leading cause of death in 2003 among persons 65 years of age and older. 4 There is presently no cure and inadequate amelioration for this condition. It can not only strip personality and capability, but is demanding on family members, seriously disrupting their lives and their work. It is expensive for the long term care system, where about half of the residents may suffer from dementia, a substantial proportion of whom can no longer afford their own care. Although people are now reaching their older years in better health, 5,6 it remains to be seen whether there will be a decrease in the incidence of AD. Currently the fastest growing element of the population is among those 85 years of age and older, the age group where the incidence of AD is greatest.A major step in the management of a disease lies in accurate diagnosis. Relevant to current work, clinical diagnostic criteria for dementia and AD were specified about 25 years ago, and the...

show abstract

Section: Cerad's Legacymentioning

confidence: 99%

Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty years

Fillenbaum

Belle

Morris

et al. 2008

Alzheimer's & Dementia

Self Cite

372

274

View full text Add to dashboard Cite

show abstract

“…Because recruitment methods vary, UDS participants are best described as a clinical case series of patients from each ADC. Additional details about the UDS sample are found elsewhere (25). Data collected between September 2005 and December 2015 were included in this study.…”

Section: Participantsmentioning

confidence: 99%

Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition

Besser

Alosco

Gómez

et al. 2016

J Neuropathol Exp Neurol

Self Cite

View full text Add to dashboard Cite

Vascular risk factors (VRFs) have been associated with clinically diagnosed Alzheimer disease (AD), but few studies have examined the association between VRF and AD neuropathology (ADNP) in cognitively normal individuals. We used longitudinal data from the National Alzheimer's Disease Center's Uniform Data Set and Neuropathology Data Set to examine the association between VRF and ADNP (moderate to frequent neuritic plaques; Braak stage III-VI) in those with normal cognition. Our sample included 53 participants with ADNP and 140 without ADNP. Body mass index (BMI), resting heart rate (HR), and pulse pressure (PP) were measured at each visit; values were averaged across participant visits and examined annual change in BMI, PP, and HR. Hypertension, diabetes, and hypercholesterolemia were self-reported. In the multivariable logistic regression analyses, average BMI and HR were associated with lower odds of ADNP, and annual increases in HR and BMI were associated with higher odds of ADNP. A previously experienced decline in BMI or HR in late-life (therefore, currently low BMI and low HR) as well as a late-life increase in BMI and HR may indicate underlying AD pathology. Additional clinicopathological research is needed to elucidate the role of changes in late-life VRF and AD pathogenesis.

show abstract

“…This is the case of the logical memory test, where one reproduces a story after listening to it. The higher the number of recalled elements from the narrative, the higher the memory score (Wechsler, 1997;Bayles and Tomoeda, 1991;Morris et al, 2006). However, the main difficulties in applying these tests are: (i) time required, since it is a manual task; and (ii) the subjectivity of the clinician.…”

Section: Introductionmentioning

confidence: 99%

Sentence Segmentation in Narrative Transcripts from Neuropsychological Tests using Recurrent Convolutional Neural Networks

Treviso

Shulby

Aluísio

2017

Proceedings of the 15th Conference of the European Chapter of The Association for Computational Linguistics: Volume 1

View full text Add to dashboard Cite

Automated discourse analysis tools based on Natural Language Processing (NLP) aiming at the diagnosis of languageimpairing dementias generally extract several textual metrics of narrative transcripts. However, the absence of sentence boundary segmentation in the transcripts prevents the direct application of NLP methods which rely on these marks to function properly, such as taggers and parsers. We present the first steps taken towards automatic neuropsychological evaluation based on narrative discourse analysis, presenting a new automatic sentence segmentation method for impaired speech. Our model uses recurrent convolutional neural networks with prosodic, Part of Speech (PoS) features, and word embeddings. It was evaluated intrinsically on impaired, spontaneous speech, as well as, normal, prepared speech, and presents better results for healthy elderly (CTL) (F 1 = 0.74) and Mild Cognitive Impairment (MCI) patients (F 1 = 0.70) than the Conditional Random Fields method (F 1 = 0.55 and 0.53, respectively) used in the same context of our study. The results suggest that our model is robust for impaired speech and can be used in automated discourse analysis tools to differentiate narratives produced by MCI and CTL.

show abstract

The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers

Cited by 793 publications

References 15 publications

Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty years

Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty years

Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition

Sentence Segmentation in Narrative Transcripts from Neuropsychological Tests using Recurrent Convolutional Neural Networks

Contact Info

Product

Resources

About